AT514707T - Immunological methods and compositions for the treatment of disease of alzheimer - Google Patents

Immunological methods and compositions for the treatment of disease of alzheimer

Info

Publication number
AT514707T
AT514707T AT03711746T AT03711746T AT514707T AT 514707 T AT514707 T AT 514707T AT 03711746 T AT03711746 T AT 03711746T AT 03711746 T AT03711746 T AT 03711746T AT 514707 T AT514707 T AT 514707T
Authority
AT
Austria
Prior art keywords
alzheimer
disease
compositions
treatment
immunological methods
Prior art date
Application number
AT03711746T
Other languages
German (de)
Inventor
George-Hyslop Peter St
Joanne Mclaurin
Original Assignee
Univ Toronto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US37391402P priority Critical
Application filed by Univ Toronto filed Critical Univ Toronto
Priority to PCT/CA2003/000502 priority patent/WO2003089460A1/en
Publication of AT514707T publication Critical patent/AT514707T/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711Alzheimer's disease; Amyloid plaque core protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
AT03711746T 2002-04-19 2003-04-07 Immunological methods and compositions for the treatment of disease of alzheimer AT514707T (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US37391402P true 2002-04-19 2002-04-19
PCT/CA2003/000502 WO2003089460A1 (en) 2002-04-19 2003-04-07 Immunological methods and compositions for the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
AT514707T true AT514707T (en) 2011-07-15

Family

ID=29251102

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03711746T AT514707T (en) 2002-04-19 2003-04-07 Immunological methods and compositions for the treatment of disease of alzheimer

Country Status (18)

Country Link
US (5) US20030232758A1 (en)
EP (2) EP2330113B1 (en)
JP (3) JP4662719B2 (en)
KR (1) KR100994748B1 (en)
CN (1) CN100360555C (en)
AT (1) AT514707T (en)
AU (1) AU2003218560B2 (en)
CA (1) CA2481952C (en)
ES (1) ES2368907T3 (en)
HK (2) HK1072947A1 (en)
IL (3) IL164643D0 (en)
MX (1) MXPA04010255A (en)
NO (2) NO335192B1 (en)
NZ (1) NZ536064A (en)
PL (1) PL209696B1 (en)
SG (1) SG173214A1 (en)
WO (1) WO2003089460A1 (en)
ZA (1) ZA200408811B (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5362164B2 (en) 2000-07-07 2013-12-11 バイオアークティック ニューロサイエンス アーベー Prevention and treatment of Alzheimer's disease
CA2504349A1 (en) * 2001-11-02 2003-05-15 Diagenics International Corporation Monoclonal antibodies specific for beta-amyloid
US20050106626A1 (en) * 2002-10-20 2005-05-19 George Pieczenik Ligand binding of amyloid peptide protein epitope
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β (1-42) oligomers, processes for their preparation and their use
JP5930573B2 (en) 2007-03-01 2016-06-15 プロビオドルグ エージー A new use of glutaminyl cyclase inhibitors
SE0401601D0 (en) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
US8193250B2 (en) 2004-10-22 2012-06-05 Mount Sinai School Of Medicine Compositions and methods for treating alzheimer's disease and related disorders and promoting a healthy nervous system
JP2008519988A (en) * 2004-11-12 2008-06-12 イーラン ファーマスーティカルズ、インコーポレイテッド A method of measuring the beta peptide - amyloid
PT1954718E (en) 2005-11-30 2014-12-16 Abbvie Inc Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
AU2006320392B2 (en) 2005-11-30 2013-01-17 AbbVie Deutschland GmbH & Co. KG Monoclonal antibodies against amyloid beta protein and uses thereof
RS53291B (en) 2005-12-12 2014-08-29 Ac Immune S.A. A beta 1-42 specific monoclonal antibodies with therapeutic properties
KR20080103560A (en) 2006-02-22 2008-11-27 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 Peptide vaccine for inducing production of anti-amyloid-beta;-peptide antibody
CA2630344C (en) 2006-03-23 2015-04-28 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
DE112007001030T5 (en) * 2006-04-28 2009-02-26 Kagoshima University Amyloid-beta peptide fibrillogenesis-inhibiting
EP2046833B9 (en) 2006-07-14 2014-02-19 AC Immune S.A. Humanized antibody against amyloid beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008143708A2 (en) * 2006-12-07 2008-11-27 Mayo Foundation For Medical Education And Research Methods and materials related to anti-amyloid antibodies
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich Isolated human antibody which is capable of selectively recognizing a neoepitope of a disorder-associated protein, a polynucleotide encoding the antibody, a vector comprising the polynucleotide, a host cell comprising the polynucleotide or the vector, a composition comprising the antibody and methods and uses associated therewith
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
EP2238166B1 (en) 2007-10-05 2013-11-27 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
EP2328908A4 (en) * 2008-08-28 2012-11-28 Univ New York State Res Found Treatment of amyloidoses using myelin basic protein and fragments thereof
US8912145B2 (en) 2008-11-28 2014-12-16 Hokko Chemical Industry Co., Ltd. Vaccine composition for prophylaxis and/or therapy of Alzheimer's disease
WO2010061899A1 (en) * 2008-11-28 2010-06-03 北興化学工業株式会社 Transformed soybean plant which stores vaccine, and use thereof
CN101797493B (en) * 2009-02-06 2014-05-21 上海抗体药物国家工程研究中心有限公司 Method for preparing affinity chromatography medium in reaction kettle
CN101486768B (en) 2009-02-25 2012-05-30 吉林大学 Antigen protein for treating Alzheimer's disease and protein gene
EP2475428B1 (en) 2009-09-11 2015-07-01 Probiodrug AG Heterocylcic derivatives as inhibitors of glutaminyl cyclase
ES2586231T3 (en) 2010-03-03 2016-10-13 Probiodrug Ag Glutaminyl cyclase inhibitors
CN102791704B (en) 2010-03-10 2015-11-25 前体生物药物股份公司 Glutaminyl cyclase (qc, ec 2.3.2.5) heterocyclic inhibitors
CA2796339A1 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
JP5945532B2 (en) 2010-04-21 2016-07-05 プロビオドルグ エージー Benzimidazole derivatives as inhibitors of glutaminyl cyclase
CN103179981B (en) 2010-07-30 2017-02-08 Ac免疫有限公司 Safe and functional humanized anti-amyloid antibodies β-
MX358739B (en) 2010-08-14 2018-09-03 Abbvie Inc Star Amyloid-beta binding proteins.
US20120321694A1 (en) * 2010-10-27 2012-12-20 Daniel Larocque Compositions and uses
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
DE102011057019A1 (en) * 2011-12-23 2013-06-27 Forschungszentrum Jülich GmbH Standard for quantification of pathogenic aggregates of endogenous proteins
CA2848994A1 (en) * 2012-01-20 2013-07-25 Ananth Annapragada Methods and compositions for objectively characterizing medical images
EP3027205A4 (en) 2013-07-28 2017-07-19 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
US20170049810A1 (en) * 2014-04-29 2017-02-23 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
BR112016030774A2 (en) 2014-07-10 2018-01-16 Bioarctic Neuroscience Ab antibody or antigen binding fragment thereof, use of an antibody, methods for reducing the amount of protofibrils of ?? in an individual, for the treatment and / or prophylaxis of a disease, for measuring the amount of protofibrils of ?? and / or protein ?? aggregate in a person, and for the diagnosis of a disease, and pharmaceutical composition
EP3461819A1 (en) 2017-09-29 2019-04-03 Probiodrug AG Inhibitors of glutaminyl cyclase

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CZ282235B6 (en) 1992-06-25 1997-06-11 Smithkline Beecham Biologicals (S.A.) Inoculation substance, process of its preparation and use
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5840294A (en) 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
US5759551A (en) 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
WO1994025060A1 (en) * 1993-04-27 1994-11-10 Ladd Anna E Immunogenic lhrh peptide constructs and synthetic universal immune stimulators for vaccines
US5744144A (en) 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
BR9608199B1 (en) 1995-04-25 2009-05-05 vaccine composition comprising an antigen, QS21 and a sterol.
WO1997007402A1 (en) 1995-08-17 1997-02-27 The Ontario Cancer Institute Protein fibril assembly assay
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6750324B1 (en) * 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
AT499832T (en) 2000-06-20 2011-03-15 Univ Toronto Transgenic animal model for neurodegenerative diseases
US6310810B1 (en) 2000-07-14 2001-10-30 Raj Kumar Jain High-speed sense amplifier
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide

Also Published As

Publication number Publication date
IL164643A (en) 2011-11-30
JP5345920B2 (en) 2013-11-20
EP1497321B1 (en) 2011-06-29
ZA200408811B (en) 2005-07-27
AU2003218560A1 (en) 2003-11-03
WO2003089460A1 (en) 2003-10-30
IL196532A (en) 2013-02-28
NO20131483A (en) 2005-01-18
ES2368907T3 (en) 2011-11-23
EP2330113B1 (en) 2016-06-29
PL209696B1 (en) 2011-10-31
US20140212481A1 (en) 2014-07-31
CA2481952C (en) 2013-10-29
US20120315321A1 (en) 2012-12-13
SG173214A1 (en) 2011-08-29
JP2013075898A (en) 2013-04-25
HK1158665A1 (en) 2017-08-11
NZ536064A (en) 2008-06-30
US20090041771A1 (en) 2009-02-12
IL164643D0 (en) 2005-12-18
MXPA04010255A (en) 2008-03-04
CN100360555C (en) 2008-01-09
EP2330113A1 (en) 2011-06-08
NO335192B1 (en) 2014-10-20
JP2006505502A (en) 2006-02-16
EP1497321A1 (en) 2005-01-19
NO20045021A (en) 2005-01-18
KR100994748B1 (en) 2010-11-17
JP4662719B2 (en) 2011-03-30
IL196532D0 (en) 2009-09-22
CN1646559A (en) 2005-07-27
PL373450A1 (en) 2005-08-22
JP2010065046A (en) 2010-03-25
KR20040108747A (en) 2004-12-24
CA2481952A1 (en) 2003-10-30
US20030232758A1 (en) 2003-12-18
HK1072947A1 (en) 2012-01-06
AU2003218560B2 (en) 2009-09-03
US20160297876A1 (en) 2016-10-13

Similar Documents

Publication Publication Date Title
DE60234514D1 (en) Elektrochirurigscher hemostat for atrial treatment and process
DE60010722D1 (en) Dibenzopyrane as glucocorticoid-receptor antagonists for the treatment of diabetic disease
AT343562T (en) Compounds and methods for the treatment of Alzheimer's disease
AT401066T (en) Methods for treatment of eating disorders
DE60335560D1 (en) Compositions containing citric acid for treatment of nail fungal diseases
AT489955T (en) A method and composition for the treatment of peripheral vascular disease
DE60141872D1 (en) of the same shape-memory alloy and method of treatment
AT537264T (en) Methods and compositions for the directed mikrowellenchemiie
DE60325690D1 (en) Semiconductor device and process for its manufacture
DE60136099D1 (en) Compositions for the treatment and diagnosis of ovarian cancer
DE69536017D1 (en) Methods and compositions for the treatment of glomerulonephritis
DE60220422D1 (en) Substituted pyrazoloverbindungen for treatment of inflammation
DE602004026173D1 (en) Methods and devices for the sustained release of more drugs
DE60336009D1 (en) Device and process for the preparation of radioisotopes
DE50309422D1 (en) Cosmetic pad and process for its manufacture
DE602004027476D1 (en) Compositions and methods of formulation for enteralprodukte that contain sialic acid
DE69508093D1 (en) Substituted piperidines for the treatment of allergic diseases
DE602004020455D1 (en) Template for treatment of hemorrhoids
DE69916875D1 (en) Lanthanide halide compositions for the treatment of water and process
DE60025812D1 (en) Jak-3 inhibitor for the treatment of allergic disorders
AT435012T (en) A process for the treatment of Parkinson's disease
DE60134003D1 (en) Methods and compositions for the prevention and treatment of anemia
DE502004008604D1 (en) Pyrrolopyridine-substituted benzene derivatives for the treatment of cardiovascular diseases
DE60223058D1 (en) Compositions and methods for treating diabetes
AT512163T (en) Administration of agents for the treatment of inflammation

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties